Pfizer And Moderna’s Cold War On COVID Gets Competitive
Biotech Talks Up Refrigeration Advantage
Ahead of anticipated emergency use approvals, Pfizer and Moderna are promoting the benefits of their rival mRNA vaccines.
You may also be interested in...
Topline results have produced a lower efficacy rate than seen in the Pfizer and Moderna trials, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.